Evidence map›Paper›PMID 31138232›Full record

ArticleBMC public health2019

Oral and anal high-risk human papilloma virus infection in HIV-positive men who have sex with men over a 24-month longitudinal study: complexity and vaccine implications.

Saverio Giuseppe Parisi, Monica Basso, Renzo Scaggiante, Samantha Andreis, Carlo Mengoli, Mario Cruciani, Claudia Del Vecchio, Nicola Menegotto, Daniela Zago, Loredana Sarmati and 2 more

Open access · goldAbstract read
In one paragraph

Article in BMC public health, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 2 pooled it
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 2 syntheses or guidelines pooled it, 14 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 1 country.

Saverio Giuseppe ParisiDepartment of Molecular Medicine, University of Padova, Via Gabelli 63, 35100, Padova, Italy. saverio.parisi@unipd.it.
Monica BassoDepartment of Molecular Medicine, University of Padova, Via Gabelli 63, 35100, Padova, Italy. monica.basso@unipd.it.ORCID http://orcid.org/0000-0003-4575-2129
Renzo ScaggianteInfectious Diseases Unit, Padova Hospital, Via Giustiniani, 2 -, 35128, Padova, Italy.
Samantha AndreisDepartment of Molecular Medicine, University of Padova, Via Gabelli 63, 35100, Padova, Italy.
Carlo MengoliDepartment of Molecular Medicine, University of Padova, Via Gabelli 63, 35100, Padova, Italy.
Mario CrucianiCenter of Diffusive Diseases, ULSS 9, Via Campania 1, 37136, Verona, Italy.
Claudia Del VecchioDepartment of Molecular Medicine, University of Padova, Via Gabelli 63, 35100, Padova, Italy.
Nicola MenegottoDepartment of Molecular Medicine, University of Padova, Via Gabelli 63, 35100, Padova, Italy.
Daniela ZagoDepartment of Molecular Medicine, University of Padova, Via Gabelli 63, 35100, Padova, Italy.
Loredana SarmatiClinical Infectious Diseases, Tor Vergata University, Viale Oxford, 81, 00133, Rome, Italy.
Massimo AndreoniClinical Infectious Diseases, Tor Vergata University, Viale Oxford, 81, 00133, Rome, Italy.
Giorgio PalùDepartment of Molecular Medicine, University of Padova, Via Gabelli 63, 35100, Padova, Italy.
University of Padua · ITUniversity of Rome Tor Vergata · ITSanta Maria Nuova Hospital · ITUniversity of Verona · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundFew studies focused on longitudinal modifications over time of high-risk HPV (HR-HPV) at anal and oral sites in HIV+ men who have sex with men (MSM).

methodsWe described patterns and longitudinal changes of HR-HPV detection and the prevalence of HR-HPV covered by the nonavalent HPV vaccine (vax-HPV) at oral and anal sites in 165 HIV+ MSM followed in an Italian hospital. The samples were collected at baseline and after 24 months (follow-up). The presence of HPV was investigated with Inno-LiPA HPV Genotyping Extra II.

resultsMedian age was 44 years (IQR 36-53), median CD4+ cell count at nadir was 312 cells/mm

conclusionsWe believe that it is important testing multiple sites over time in HIV-positive MSM. ART seems to protect men from anal HR-HPV confirmed detection. Vaccination programmes could reduce the number of HR-HPV genotypes at anal site and the risk of the first HR-HPV acquisition at the oral site.

Indexed as

AdultAnal CanalHIV InfectionsHomosexuality, MaleHumansItalyLongitudinal StudiesMaleMiddle AgedMouthPapillomavirus InfectionsPapillomavirus VaccinesRisk AssessmentPapillomavirus VaccinesAnalHigh risk HPVHIV infectionMen who have sex with menOral

Identifiers

PMID31138232
PMCPMC6537447
OpenAlexW2947871813

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.